The treatments available for multiple sclerosis (MS) have greatly increased in recent years. Some of the newer, more potent disease modifying therapies (DMTs) are associated with more complex safety profiles. The goal of this program is to support clinicians in understanding the safety concerns and monitoring requirements for patients taking DMTs.
This program has received an unrestricted educational grant or in-kind support from Roche.
Mohammed Al Jumah, MBBS, MD, FRCPC
Rola Alarieh, MSN, BSN, CNS, RN
This current CME Course is part of a multi-component learning series.
This learning series is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and is approved by Queens University and accredited by the Saudi Commission for Health Specialties for up to 5.5 CPD hour(s) for the completion of all components within the series.
Credits are reported to the Saudi Commission for Health Specialties on a monthly basis. Please ensure that your Saudi Commission ID is accurate in your profile and allow sufficient time for credits to appear in your Mustamir account.
Upon completion of this continuing education program, participants will be better able to: